Understanding the window of opportunity concept in early rheumatoid arthritis

Arthritis and Rheumatism

Volumn 48, Issue 7, 2003, Pages 1771-1774

  Boers, Maarten ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; EDITORIAL; HUMAN; JOINT PROSTHESIS; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; META ANALYSIS; PHYSICAL DISABILITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS;

EID: 0038005092     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11156     Document Type: Editorial

References (13)

1. Wilske KR, Healey LA. Remodeling the pyramid: a concept whose time has come. J Rheumatol 1989;16:565-7.
2. Landewe RBM. The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum 2003;48:1-5.
3. Verstappen SMM, Jacobs JWG, Bijlsma JWJ, Heurkens AHM, van Booma-Frankfort C, Jan ter Borg E, et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs verus treatment according to the pyramid approach in the first year. Arthritis Rheum 2003;48:1797-807.
4. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [published erratum appears in Lancet 1998;351:220]. Lancet 1997;350:309-18.
5. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van De Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
6. Van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blaauw AA, Kruize AA, Hofman DM, et al. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. Ann Rheum Dis 2000;59:468-77.
7. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
8. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
9. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FinRACo trial group. Lancet 1999;353:1568-73.
10. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-8.
11. Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003;48:46-53.
12. Landewe RBM, Boers M, Verhoeven AC, Boonen A, van der Heijde DMFM, van der Linden S. A longitudinal analysis of the relationship between change in DAS28 and change in radiological progression rate [abstract]. Arthritis Rheum 2001;44 Suppl 9:S175.
13. Welsing PMJ, Swinkels HL, van Gestel AM, van Riel PLCM. The relation between disease activity and radiologic progression of joint damage in rheumatoid arthritis [abstract]. Arthritis Rheum 2001;44 Suppl 9:S277.